Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization

Nutrition and Cancer

Volumn 61, Issue 3, 2009, Pages 310-321

  Touil, Yasmine S ^a,b,c   Fellous, Arlette ^d   Scherman, Daniel ^a,b,c   Chabot, Guy G ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYFLAVONE; 3',4' DIHYDROXYFLAVONE; 7 HYDROXYFLAVONE; ACACETIN; ALPHA TUBULIN; APIGENIN; AURANTIIN; BAICALEIN; CENTAUREIDIN; CHRYSIN; COLCHICINE; COMBRETASTATIN A4; CYTOCHALASIN D; DOCETAXEL; FISETIN; FLAVONOID; GALANGIN; ISOQUERCITRIN; KAEMPFEROL; LUTEOLIN; LUTEOLIN 7 GLUCOSIDE; MITOFLAXONE; MORIN; MYRICETIN; NARINGENIN; PRIMULETIN; QUERCETIN; RHAMNETIN; RUTOSIDE; UNCLASSIFIED DRUG; TUBULIN;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER RESISTANCE; CANCER THERAPY; CHEMICAL BOND; CONTROLLED STUDY; DEPOLYMERIZATION; DIHYDROXYLATION; DRUG ACETYLATION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; LEWIS CARCINOMA; MELANOMA B16; MICROTUBULE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; ACETYLATION; ANIMAL; CHEMISTRY; CYTOLOGY; CYTOSKELETON; DRUG EFFECT; EXPERIMENTAL MELANOMA; METABOLISM; MOUSE; PATHOLOGY;

ACETYLATION; ANIMALS; CARCINOMA, LEWIS LUNG; CYTOSKELETON; ENDOTHELIAL CELLS; FLAVONOIDS; MELANOMA, EXPERIMENTAL; MICE; MICROTUBULES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 67649391407     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802521346     Document Type: Article

References (38)

1. Kerbel RS:Molecular origins of cancer: tumor angiogenesis. N Engl J Med 358, 2039-2049, 2008.
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31, 1995.
3. Carmeliet P and Jain RK:Angiogenesis in cancer and other diseases. Nature 407, 249-257, 2000.
4. Taraboletti G and Margosio B: Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 1, 378-384, 2001.
5. Tozer GM, Kanthou C, and Baguley BC: Disrupting tumor blood vessels. Nat Rev Cancer 5, 423-435, 2005.
6. Hurwitz H, Fehrenbacher L, NovotnyW, Cartwright T, Hainsworth J, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342, 2004.
7. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, et al.: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23, 3697-3705, 2005.
8. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, et al.: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23, 792-799, 2005.
9. Siemann DW, Chaplin DJ, and Horsman MR: Vascular-targeting therapies for treatment of malignant disease. Cancer 100, 2491-2499, 2004.
10. Siemann DW: Vascular targeting agents. Horizons in Cancer Therapeutics: From Bench to Bedside 3, 4-15, 2002.
11. Aherne SA and O'Brien NM: Dietary flavonols: chemistry, food content, and metabolism. Nutrition 18, 75-81, 2002.
12. Lopez-Lazaro M: Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem Anticancer Agents 2, 691-714, 2002.
13. Middleton E Jr, Kandaswami C, and Theoharides TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52, 673-751, 2000.
14. Havsteen BH: The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96, 67-202, 2002.
15. Hill S,WilliamsKB, andDenekamp J:Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol 25, 1419-1424, 1989.
16. Monasterio A, Urdaci MC, Pinchuk IV, Lopez-Moratalla N, and Martinez- Irujo JJ: Flavonoids induce apoptosis in human leukemiaU937 cells through caspase- and caspase-calpain-dependent pathways. Nutr Cancer 50, 90-100, 2004.
17. Edgell CJ, McDonald CC, and Graham JB: Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 80, 3734-3737, 1983.
18. Bouis D, Hospers GA, Meijer C, Molema G, and Mulder NH: Endothelium in vitro: a review of human vascular endothelial cell lines for blood vesselrelated research. Angiogenesis 4, 91-102, 2001.
19. Abramoff MD,Magelhaes PJ, and Ram SJ: Image processing with ImageJ. Biophotonics Int 11, 36-42, 2004.
20. Verschueren H, Houben B, De Braekeleer J, De Wit J, Roggen D, et al.: Methods for computer assisted analysis of lymphoid cell shape and motility, including Fourier analysis of cell outlines. J Immunol Methods 163, 99-113, 1993.
21. Shelanski ML, Gaskin F, and Cantor CR: Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci USA 70, 765-768, 1973.
22. Fellous A, Francon J, Lennon AM, and Nunez J: Microtubule assembly in vitro: purification of assembly-promoting factors. Eur J Biochem 78, 167-174, 1977.
23. Zavala F, Guenard D, Robin JP, and Brown E: Structure-antitubulin activity relationship in steganacin congeners and analogues: inhibition of tubulin polymerization in vitro by (+/-)-isodeoxypodophyllotoxin. J Med Chem 23, 546-549, 1980.
24. Westermann S and Weber K: Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 4, 938-947, 2003.
25. Beutler JA, Hamel E, Vlietinck AJ, Haemers A, Rajan P, et al.: Structureactivity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem 41, 2333-2338, 1998.
26. Galbraith SM, Chaplin DJ, Lee F, StratfordMR, Locke RJ, et al.: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo. Anticancer Res 21, 93-102, 2001.
27. Dupeyre G, Chabot GG, Thoret S, Cachet X, Seguin J, et al.: Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents. Bioorg Med Chem 14, 4410-4426, 2006.
28. Etienne-Manneville S: Actin and microtubules in cell motility: which one is in control? Traffic 5, 470-477, 2004.
29. Lee JS and Gotlieb AI: Microtubules regulate aortic endothelial cell actin microfilament reorganization in intact and repairing monolayers. Histol Histopathol 20, 455-465, 2005.
30. Falconer MM, Vielkind U, and Brown DL: Establishment of a stable, acetylated microtubule bundle during neuronal commitment. Cell Motil Cytoskeleton 12, 169-180, 1989.
31. Schatten G, Simerly C, Asai DJ, Szoke E, Cooke P, et al.: Acetylated alphatubulin in microtubules during mouse fertilization and early development. Dev Biol 130, 74-86, 1988.
32. Hanemaaijer R and Ginzburg I: Involvement of mature tau isoforms in the stabilization of neurites in PC12 cells. J Neurosci Res 30, 163-171, 1991.
33. Mack TG, Koester MP, and Pollerberg GE: The microtubule-associated protein MAP1B is involved in local stabilization of turning growth cones. Mol Cell Neurosci 15, 51-65, 2000.
34. Gamblin TC, Nachmanoff K, Halpain S, and Williams RC Jr: Recombinant microtubule-associated protein 2c reduces the dynamic instability of individual microtubules. Biochemistry 35, 12576-12586, 1996.
35. Manach C,Williamson G,Morand C, Scalbert A, and Remesy C: Bioavailability and bioefficacy of polyphenols in humans: I. review of 97 bioavailability studies. Am J Clin Nutr 81, 230S-242S, 2005.
36. Walle T, Wen X, and Walle UK: Improving metabolic stability of cancer chemoprotective polyphenols. Expert Opin Drug Metab Toxicol 3, 379-388, 2007.
37. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, et al.: Flavonoids, dietaryderived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res 57, 2916-2921, 1997.
38. Joussen AM, Rohrschneider K, Reichling J, Kirchhof B, and Kruse FE: Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids. Exp Eye Res 71, 483-487, 2000.